However, in methionine-choline deficient diet-induced models of NAFLD, overexpression of PPARγ or treatment with PPARγ agonists, including rosiglitazone and pioglitazone, has been shown to improve hepatic steatosis and liver lesions [18–21], whereas heterozygous deficiency in PPARγ or administration of PPARγ antagonists led to an increase in steatosis and lesions [19]. Here, PPARG is linked to metabolic dysfunction-associated steatotic liver disease.